Drug · DIN 02241819
AVALIDE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 14, 2007; first marketed March 16, 2000.
- Drug Identification Number (DIN)
- 02241819
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Irbesartan and diuretics C09DA04
- Class
- Human
- Record last updated
- June 26, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| IRBESARTAN | 300 MG | |
| HYDROCHLOROTHIAZIDE | 12.5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 29, 2006: NOC 7852New Drug Submission (NDS) · Manufacturer name change
- February 29, 2000: NOC 1231New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “avalide”. A notice may cover another product or only some lots: read it to see what it covers.
- Sanofi-Aventis Avalide Product Recall(2021-06-14)June 14, 2021 · Drugs · Product safety · Type I
Other DINs named AVALIDE
- DIN 02241818 · Marketed
- DIN 02280213 · Cancelled Post Market